Main Article Content


The Common fruit Caprificus Insectifera is a deciduous treegrowing to heights of up to 6 meters (19 ft).When it comes to nutritional fruits, fruits can hold their place against any other fruit. This remarkable fruit has a history dating 5000 years. The fruits contain a high amount (70%) of sugar (glucose and fructose in the same quantity), pectins, flavonoids and vitamins. It is proposed that the flavonoids contained in the fruit aqueous extract may contribute to the hypolipidemic action. Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health, leading to reduced life expectancy and/or increased health problems. Obesity is often associated with the increasing of a number of chronic diseases such as Insulin resistance diabetes mellitus, Hypertension, Hypercholesterolemia, Cerebrovascular accident (CVA), Heart attack, Congestive cardiac diseases, Cancer, Gallstone formation, Gout, etc. The anti-obesity effect of fig fruit in animals fed on cafeteria and atherogenic diet was evaluated. The animals were divided into three major group’s viz. Normal diet, Cafeteria diet and Atherogenic diet. Under these groups, they were further divided into five sub-groups. The first sub-group consists of control animals and they were not treated with any drug. The second sub-group was treated with the standard drug, i.e. Ayurslim. The third, fourth and fifth sub-groups were treated with fig extract at the dose of 200, 300 and 400 mg/kg respectively. The treatment period was 40 days. After 40 days, change in body weight, lipid profile and CNS activity were evaluated in all the groups and it was found that the fig extract showed anti obesity activity by decreasing the body weight and the levels of total cholesterol.


Caprificus Insectifera Hypercholesterolemia Diabetes Mellitus Cafeteria Diet Atherogenic Diet

Article Details

How to Cite
Sai Jyothi Ausali, Ramya sree D, & Swathi Vadduri. (2021). Screening of Anti-Hyperlipidaemic Activity of Caprificus Insectifera in Albino rats feed with high fat diet. International Journal of Research in Pharmacology & Pharmacotherapeutics, 10(3), 257-267. Retrieved from


  1. 1 Obesity: Preventing and managing the global epidemic. WHO Technical Report Series – 894, Report of a WHO consultation. Geneva: World Health Organization; 1998.
  2. 2 Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5thed. New Delhi: Elsevier; 2003.
  3. 3 Garg C, Khan SA, Ansari SH, Garg M. Prevalence of obesity in Indian women. Obes Rev 2010; 11 (2):105-8.
  4. 4 Jebb SA. Aetiology of Obesity. In: Finer N, Editor. Obesity. Vol. 53(2). London: British Medical Bulletin, Royal society of medicine press limited;1997.
  5. 5 Kulkarni SK, Kaur G.Obesity: An insight into its neurochemical basis and treatment. Indian J Pharmacol 1999; 31: 388-403.
  6. 6 Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y etal. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114:1752-61.
  7. 7 FardetA, Llorach R, Martin JF, Besson C, Lyan B, Pujos-Guillot E. A liquid chromatography-quadrupole time-of-flight (LC-QTOF)-based metabolomic approach reveals new metabolic effects of catechin in rats. J Proteome Res 2008; 7:2388-98.
  8. 8 Han LH, Sumiyoshi M, Zhang J, Liu MX, Zhang XF, Zheng YN et al. Antiobesity action of Salix matsudanaleaves (Part 1). Antiobesity action of polyphenols of Salix matsudanain high fat diet treated rodent animals. Phytother Res 2003; 17:1188-94.
  9. 9 Ali O. Get to grips with obesity – Pharmacotherapy. The Pharmaceutical Journal 2002; Padwal RS, Majumdar SR. Drug treatments for obesity: Orlistat, Sibutramine and Rimonabant. Lancet 2007; 369:71-77.
  10. 10 Han LK, Kimura Y, Okuda H.Antiobesity effects of natural products. Stud Nat Prod Chem 2005a; 30:79-110.
  11. 11 Warrier PK, Nambiar VPK, Ramankutty C. Indian Medicinal Plants: A Compendium of 500 Species. Chennai, India: Orient Longman Ltd;1994.
  12. 12 Chadhya YR. The Wealth of India: A dictionary of Indian raw materials and industrial Products. New Delhi, India: Publications and Information Directorate;1987.
  13. 13 Pi-Sunyer X. The Medical risks of obesity. Post Grad Med 2009; 121 (6):21-33.
  14. 14 BurniatW, Cole T, Lissau I, Poskitt E. Child and Adolescent Obesity: Causes and Consequences, Prevention and Management. Cambridge, United Kingdom: Cambridge University Press;2002.
  15. 15 WHO/IASO/IOTF. The Asia-Pacific perspective: Redefining obesity and itstreatment. Australia, Melbourne: Health Communications; 2000.
  16. 16 Vague J. The degree of masculine differentiation of obesities; the factor determining predisposition to diabetes, atherosclerosis, gout and uric acid calculus disease. Am J Clin Nutr 1956; 4:20-34.
  17. 17 Reaven GM. Role of insulin resistance in human disease. Diabetes 1998; 37: 1595- 1607.
  18. 18 Farooqi S, Rahilly S. Genetics of obesity in humans. Endocr Rev 2006; 27(7):710-18.
  19. 19 Weinsier RL, Hunter GR, Heini AF, Goran MI, Sell SM. The etiology of obesity: relative contribution of metabolic factors, diet and physical activity. Am J Med 1998; 105(2):145-150.
  20. 20 Fitzgerald PA, Tierney LM, Mcphee SJ et al. Common presentations in endocrinology; obesity - Current Medical Diagnosis and Treatment. New Delhi: Lange Medical Books; 2003.
  21. 21 268:687-89.
  22. 22 Bray GA. Strategies for discovering drugs to treat obesity. In: Kopelman PG, Stock MJ, Editors. Clinical Obesity. Oxford: Blackwell Science;1998.
  23. 23 Wilding J, Widdowson P, Williams G. Neurobiology. In: Finer N, Editor. Obesity.Vol. 53(2). London: British Medical Bulletin, Royal society of Medicine Press Ltd; 1997.
  24. 24 Kasper DL, BraunwaldE, Fauci AS, Hauser SL, Lango DL, James JL. Harrison’s Principles of Internal Medicine. New York: Mc Graw Hill;2005.
  25. 25 Arya SN, Kumar R. Obesity: Review article. J Indian Acad Clin Med 2004; 5(2): 166- 81.
  26. 26 Collantes R, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease and the epidemic of obesity. Cleveland Clin J Med 2004; 71(8):657-64.
  27. 27 Munro JF, Patrick AW. The Management of Obesity. Medicine International 1994; 22(10):389-92.
  28. 28 Laquatra I. Nutrition for weight management. Food Nutrition and DietTherapy. Philadelphia: WB Saunders Co.; 2000.
  29. 29 Nick F, Editor. Present and future pharmacological approaches. Chapter 10 in Obesity, Vol. 53(2). London: British Medical Bulletin, Royal Society of Medicine Press Ltd.; 1997.
  30. 30 Davidson MH. Weight control and risk factor reduction in obese weight control and risk factor reduction in obese subjects treated for two years with orlistat. JAMA 1999; 281(3):235-42.
  31. 31 Hollander PA, Elbein SC, Hirsch IB. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21:1288-94.
  32. 32 DimitrorD, Koeva L, Kovatchera T. Effect of orlistat on insulin resistance, cardiovascular risk factors and serum leptin levels in obese type 2 diabetic patients. Int J Obes 2000; 24:51.
  33. 33 Stock MJ. Sibutramine: a review of the pharmacology of novel antiobesity agent. Int J Obes 1997; 21:1525-29.
  34. 34 Jones SP, Heath MJ. Long term weight loss with sibutramine; 5% responders. Int J Obes 1996; 20(54):157.
  35. 35 James WPT, AstrupA, Finer N. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 2000; 356:2119-25.
  36. 36 GanongW. Review of Medical Physiology. Connecticut: Appleton and Lange;1999.
  37. 37 Flier JS, Spiegelman BM. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-89.
  38. 38 Mohammed Ali V. Adipose tissue is an autocrine and paracrine organ. Int J Obes1998; 22:1145-58.
  39. 39 Rodbell M. Metabolism of isolated adipocytes. 1. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 1964; 239:375-80.
  40. 40 Rupnick MA, Panigrahy D, Zhang CY et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 2002; 99:10730-35.
  41. 41 Cinti S, Mitchell G, Barbatelli G etal.Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46:2347-55.
  42. 42 Krief S, Lonnqvist F, Raimbault S, Baude B et al. Tissue distribution of ß-adrenergic receptor mRNA in man. J Clin Invest 1993; 91:344-49.
  43. 43 Maria E, Trujillo, Scherer PE. Adipose Tissue-Derived Factors: Impact on Health and Disease. Endocrine Reviews 2006; 27:762-78.
  44. 44 Green H, Kehinde O. An established pre-adipose cell line and its differentiation in culture. II. Factors affecting the adipose cWolfram S, Wang Y, Thielecke F. Anti-obesity Effects of Green Tea: From Bedside to Bench. Mol Nutr Food Res 2006; 50:176-87.
  45. 45 Bays H, Blonde L, Rosenson R. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther 2006; 4(6):871-95.
  46. 46 MazzucotelliA, Lanqin D. Fatty acid mobilization and their use in adipose tissue. J Soc Biol 2006; 200(1):83-91.